Summary of Key Points
Recently, the innovative drug sector has shown a counter-trend rise amidst market volatility, with the CSI Innovative Drugs Index increasing by more than 17% in just two months. This surge is driven by a combination of several favorable factors: improved healthcare and commercial insurance payment systems, enhanced capabilities to generate revenue overseas, increasingly positive corporate performances, and continuous capital inflows. Moreover, the sector's valuation has not yet reached historical highs, indicating promising prospects for international expansion in the future.
Detailed Analysis
1. Capital Flocking In: Innovative Drugs Become a Highly Attractive Investment
Money from the market is pouring into the innovative drug sector. Data shows that 28 ETFs focused on innovative drugs have attracted over 14 billion yuan in funds in the past month, pushing their total scale beyond 130 billion yuan. Active funds have also increased their holdings in the second quarter, with companies such as WuXi AppTec and KaiLaiYing receiving significant investment from multiple funds.
Why is there such enthusiasm for these investments? The sector's clear upward trend (a 17% increase in the index over two months), coupled with supportive policies, opportunities for overseas expansion, and improving corporate performance, has convinced investors of its potential.
2. Upgraded Overseas Strategies: Moving from Selling Products to Building Partnerships
Chinese innovative drug companies are no longer simply selling their products to foreign firms for a one-time fee; instead, they are entering into collaborative partnerships for joint research and development, sharing profits, which significantly enhances their bargaining power.
Statistics Speak: In the first half of 2026, there were 82 overseas transactions totaling 96.7 billion US dollars (more than the entire amount in 2024), with upfront payments accounting for 72% of the annual total for 2025. For example, Ganli Pharmaceutical collaborated with a Brazilian company to share insulin technology, establishing a ten-year partnership that not only helped them quickly enter the local market but also paved the way for future products in 55 countries.
Benefits of This Approach: The shift from one-time sales to long-term profit-sharing models provides more stable revenue and greater profit margins.
3. Policy Support: Both Healthcare and Commercial Insurance Systems Are Boosting Sales
Policies are providing strong support for the innovative drug industry:
- For the first time this year, 16 innovative drugs (including 4 domestically developed new drugs) have been included in the essential medicine list, allowing them to reach primary care hospitals and serve a wider patient base.
- The preliminary review of the healthcare insurance drug list has approved 557 drugs, and the commercial insurance list has approved 54, expanding payment options. As a result, patients can afford these drugs, ensuring higher sales volumes for companies.
In Simple Terms: Previously, innovative drugs might have struggled to gain access due to high prices, but now policies are helping to open up new markets, eliminating concerns about unsold products.
4. Corporate Performance Improvement: Growing Profits and Room for Further Valuation Increases
The performance of innovative drug companies is improving:
- Zhaoyan New Drugs expects its profits to increase by 8-13 times in the first half of the year, thanks to both the appreciation of biological assets and strong core business operations.
- Ailisi has seen a 39% increase in both revenue and profit, driven by increased sales volumes following the expansion of healthcare coverage.
- Medixi has turned from loss-making to profit-making, with improved order volumes and pricing strategies.
Valuation Overview: The current PE (Price-to-Earnings) ratio for the innovative drugs index is 48, and the PB (Price-to-Book) ratio is 4.11, which is at a historical median level, indicating that prices are not excessively high relative to earnings and suggesting potential for further growth.
5. A Promising Future: 2027 Could Mark a Milestone for Internationalization
Guojin Securities predicts that by 2027, Chinese innovative drugs will enter a phase of global commercial sales, relying less on licensing agreements and focusing more on direct overseas market sales as a second source of growth.
Reasons for This Forecast: China's independent R&D capabilities are improving, and the pathways for overseas sales are becoming more established, reducing time and cost barriers. For instance, Ganli Pharmaceutical invests 33% of its revenue in research and development, which supports long-term growth.
Conclusion: The potential of the innovative drug sector is enormous, with favorable policies, substantial profit opportunities, attractive capital inflows, and reasonable valuations. Internationalization could lead to even greater success in the future, making this sector a worthwhile investment for both professionals and individuals looking for solid investment options.
In One Sentence
The innovative drug sector currently boasts favorable policies, high returns, strong investor interest, and reasonable valuations. With potential for further growth through international expansion, it is indeed a sector worth paying close attention to.